Company: CMND
Filing Date: 2025-12-05
Form Type: F-1/A
Source: 0001213900-25-118772
Chunk: 265

Company: Clearmind Medicine Inc.
Filing Date: 2025-12-05
Form: F-1/A
Chunk 265
---
 than the exercise price of the April 2023 Warrants, the exercise price of the April 2023 Warrants was reduced to $ 1.077, and each April 2023 Warrant became exercisable into 0.724common shares of the Company. For further details of the ratio of warrant shares issuable and outstanding in relation to the April 2023 Warrants, see detailed table in note 9.

During the period between November 29, 2023 and December 5, 2023, 2,729,394April 2023 Warrants were exercised into 652,521common shares.

During the period between March 8, 2024 and March 22, 2024, 27,973April 2023 Warrants were exercised into 20,245common shares.

On June 28, 2024, 156,098April 2023 Warrants were exercised into 112,975common shares.

On August 12, 2024, 64,104April 2023 Warrants were exercised into 46,395common shares.

| b. | On September 18, 2023, the Company issued 7,500,000 warrants in connection with its September 2023 Public Offering (“September 2023 Warrants”). The warrants include a cashless exercise provision and repricing adjustments for offerings at a price lower than the existing exercise price of the warrants, stock splits, reclassifications, subdivisions, and other similar transactions (“September 2023 Warrant Adjustments”) and therefore, these warrants were recorded at their fair value as a derivative liability at the time of the grant and are revalued at the end of each reporting period. The number of warrants does not change, however, the number of warrant shares issued may change, subject to the adjustment noted above.   On January 21, 2024, following the January 2024 Public Offering, which included the offering of common shares at a price lower than the exercise price of the September 2023 Warrants, the exercise price of the September 2023 Warrants was reduced to $1.077, and each September 2023 Warrant became exercisable into 0.288 common shares of the Company. For further details of the ratio of warrant shares issuable and outstanding in relation to the September 2023 Warrants, see detailed table in note 9.   During the period between November 29, 2023 and December 5,